Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice

Psychopharmacology

Volumn 124, Issue 4, 1996, Pages 355-364

  Johnson, N J T ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anxiety; CCK 4; CCK 8s; Devazepide; Diazepam; Ethological analysis; L 365, 260; Mice; PD135158; Plus maze

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; DIAZEPAM; PD 135158; TETRAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; ETHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; BENZODIAZEPINONES; DIAZEPAM; MALE; MICE; MOTOR ACTIVITY; PHENYLUREA COMPOUNDS; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; TETRAGASTRIN;

EID: 0030005802     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02247441     Document Type: Article

References (71)

1. Abelson JL, Nesse RM (1994) Pentagastrin infusions in patients with panic disorder. I .Symptoms and cardiovascular responses. Biol Psychiatry 36:73-83
2. Adamec RE, Shallow T (1993) Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 54:101-109
3. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A (1994) The influence of 5-hydroxytryptamine reuptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur J Pharmacol 271:403-411
4. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85
5. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder clinical and behavioral findings. Arch Gen Psychiatry 48:603-610
6. Bradwejn J, Koszycki D, Couetoux du Tertre A, Bourin M, Palmour RM, Ervin FR (1992) The cholecystokinin hypothesis of panic and anxiety disorders: a review. J Psychopharmacol 6:345-351
7. Bradwejn J, Koszycki D, Dutertre AC Vanmegen H, Denboer J, Westenberg H, Annable L (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51:486-493
8. Chopin P, Briley M (1993) The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110:409-414
9. Cole JC, Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol 4:573-580
10. Cole JC, Rodgers RJ (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test comparison with haloperidol. Psychopharmacology 114:288-296
11. Cole JC, Rodgers RJ (1995) Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 52:473-478
12. 2-adrenoceptor mediation. Psychopharmacology 118:425-436
13. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides 19:65-73
14. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15:731-755
15. B antagonist in patents with panic disorder. Biol Psychiatry 35:680
16. Dauge V, Derrien M, Durieux C, Noble F, Corringer PJ, Roques BP (1992) Effects of selective agonists for cholecystokinin receptors CCK-B in nociception and behavior in rodents. Therapie 47:531-539
17. Dawson GR, Rupniak NMJ, Iversen SD, Tricklebank MD (1994) Lack of effect of CCKB receptor antagonists in animal screens for anxiolytic drugs. J Psychopharmacol 8:A47
18. DeMontigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy-volunteers preliminary findings. Arch Gen Psychiatry 46:511-517
19. Derrien M, Durieux C, Dauge V, Roques BP (1993) Involvement of D(2) dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus-accumbens. Brain Res 617:181-188
20. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994) Heterogeneity of CCK-B receptors involved in animal-models of anxiety. Pharmacol Biochem Behav 49:133-141
21. Dourish CT, Bickerdike MJ, Stanhope KJ, Fletcher A, Marsden CT (1994) Profile of CCKA and CCKB receptor antagonists in the CER end elevated plus-maze models of anxiety in the rat: modulation by 5-HT reuptake blockade. Behav Pharmacol 5:29-30
22. Ervin FR, Palmour RM, Bradwejn J (1991) A new primate model for panic disorder. Biol Psychiatry 29:430S
23. Fink H, Rex A, Marsden CA (1994) Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety. Behav Pharmacol 5:30
24. Harro J, Vasar E (1991a) Cholecystokinin-induced anxiety how is it reflected in studies on exploratory-behavior? Neurosci Biobehav Rev 15:473-477
25. Harro J, Vasar E (1991b) Evidence that CCKB receptors mediate the regulation of exploratory behavior in the rat. Eur J Pharmacol 193:379-381
26. Harro J, Pold M, Vasar E (1990) Anxiogenic-like action of cerulein, a CCK-8 receptor agonist, in the mouse-influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg's Arch Pharmacol 341:62-67
27. Harro J, Vasar E, Bradwejn J (1993) CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249
28. Hays SE, Beinfeld MC, Jensen RT, Goodwin FK, Paul SM (1980) Demonstration of a putative receptor site for cholecystokinin in the rat brain. Neuropeptides 1:53-62
29. Hendrie CA, Dourish CT (1993) Effects of cholecystokinin tetrapeptide (CCK-4) and the CCKB antagonist LY-288513 in a putative model of panic in the mouse. Br J Pharmacol 108:26P
30. Hendrie CA, Neill JC (1992) Ethological analysis of the role of CCK in anxiety. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds) Multiple cholecystokinin receptors in the CNS. Oxford University Press, Oxford, pp 132-142
31. Hughes J, Boden P, Costall B et al. (1990) Development of a class of selective cholecystokinin type-B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87: 6728-6732
32. Innis RB, Snyder SH (1980) Cholecystokinin receptor binding in brain and pacreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. Eur J Pharmacol 65: 123-124
33. Ivy AC, Goldberg EA (1928) A hormone mechanism for gall bladder contraction and evacuation. Am J Physiol 86:599-613
34. Jensen RT, Lemp GF, Gardner JD (1980) Interaction of cholecystokinin with specific membrane receptors on pancreatic acinae cells. Proc Natl Acad Sci USA 77:2079-2083
35. Jorpes JE, Mutt V (1966) Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 66:196-202
36. Lines C, traub M, Ambrose J (1993) CCK and anxiety in normal volunteers. Neuropsychopharmacology 9:S 181-182
37. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
38. Mannisto PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E (1994) Opposite effects mediated by CCKA and CCKB receptors in behavioral and hormonal studies in rats. Naunyn-Schmiedeberg's Arch Pharmacol 349:478-484
39. Moran TH, Robinson PH, Goldrich MS, Mchugh PR (1986) 2 brain cholecystokinin receptors implications for behavioral actions. Brain Res 362:175-179
40. Newman JD, Crepeau LJ (1991) Heart rate changes following administration of putative panicogenic chemicals in squirrel monkeys. Soc Neurosci Abstr 17:420.13
41. Pavlasevic S, Bednar I, Qureshi GA, Sodersten P (1993) Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 5:225-228
42. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
43. Rataud J, Darche F, Piot O, Stutzmann JM, Bohme GA, Blanchard JC (1991) Anxiolytic effect of CCK-Antagonists on plus-maze behavior in mice. Brain Res 548:315-317
44. Ravard S, Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273
45. Ravard S, Dourish CT, Iversen SD (1990) Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L-365, 260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors. Br J Pharmacol 101:576P
46. Rehfeld JF (1992) CCK and anxiety: introduction. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds) Multiple cholecystokinin receptors in the CNS. Oxford University Press, Oxford, pp 117-120
47. Rex A, Barth T, Voigt JP, Domeney AM, Fink H (1994a) Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin-octapeptide in rat models of anxiety. Neurosci Lett 172:139-142
48. Rex A, Fink H, Marsden CA (1994b) Effects of BOC-CCK-4 and L365, 260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus-maze. Neuropharmacology 33: 559-565
49. Rodgers RJ, Cole JC (1993) Anxitey enhancement in the murine elevated plus-maze by immediate prior exposure to social stressors. Physiol Behav 53:83-388
50. Rodgers RJ, Cole JC (1994a) The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA (eds) Ethology and Psychopharmacology. Wiley, Chichester, pp 9-44
51. Rodgers RJ, Cole JC (1994b) Anxiolytic-like effect of (s)-WAY-100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol 261:321-325
52. Rodgers RJ, Johnson NJT (1995a) Cholecystokinin and anxiety: promises and pitfalls. Crit Rev Neurobio (in press)
53. Rodgers RJ, Johnson NJT (1995b) Factor analysis of the spatiotemporal and ethological measures in the murine elevated plus-maze. Pharmacol Biochem Behav 52:297-303
54. Rodgers RJ, Shepherd JK (1993) Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113:237-242
55. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze - profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621-634
56. Rodgers RJ, Lee C, Shepherd JK (1992b) Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106:102-110
57. Rodgers RJ, Cole JC, Davies A (1994a) Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav 48:959-963
58. Rodgers RJ, Nikulina EM, Cole JC (1994b) Dopamine D-1 and D-2 receptor ligands modulate the behavior of mice in the elevated plus-maze. Pharmacol Biochem Behav 49:985-995
59. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995) Ethopharmacological analysis of the effects of putative "anxiogenic" agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52 (in press)
60. Rupniak NMJ, Schaffer L, Siegl P, Iversen SD (1993) Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus-monkeys. Neuropeptides 25:115-119
61. Saito A, Goldfine ID, Williams JA (1980) Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex. J Neurochem 37:433-490
62. Sauter A, Frick W (1983) Determination of cholecystokinin tetrapeptide and cholecystokinin octapeptide sulfate in different rat-brain regions by high-pressure liquid-chromatography with electrochemical detection. Anal Biochem 133:307-313
63. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioral and pharmacological characterization of the elevated zero-maze as an animal-model of anxiety. Psychopharmacology 116:56-64
64. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991a) The behavioral properties of CI-988, a selective cholecystokinin(B) receptor antagonist. Br J Pharmacol 104:239-245
65. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991b) Evidence for an involvement of the brain cholecystokinin-B receptor in anxiety. Proc Natl Acad Sci USA 88:1130-1133
66. Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463-469
67. Vanderhaegen JJ, Signeau JC, Gepts W (1975) New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257:604-605
68. Van Megen HJGM, Westenberg HGM, Denboer JA, Haigh JRM, Traub M (1994) Pentagastrin induced panic attacks - enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455
69. Vasar E, Peuranen E, Harro J, Lang A, Oreland L, Mannisto PT (1993a) Social-isolation of rats increases the density of cholecystokinin receptors in the frontal-cortex and abolishes the antiexploratory effect of cerulein. Naunyn-Schmiedeberg's Arch Pharmacol 348:96-101
70. Vasar E, Peuranen E, Oopik T, Harro J, Mannisto PT (1993b) Ondansetron, an antagonist of 5-HT3-receptors, antagonizes the antiexploratory effect of cerulein, an agonist of CCK-receptors, in the elevated plus-maze. Psychopharmacology 110: 213-218
71. Vasar E, Lang A, Harro J, Bourin M, Bradwejn J (1994) Evidence for potentiation by CCK antagonists of the effect of cholecystokinin-octapeptide in the elevated plus-maze. Neuropharmacology 33:729-735